(Q30774968)

26 June 2017

1 reference

title

Immune therapy in inflammatory bowel disease and models of colitis (English)

1 reference

inflammatory bowel diseases

26 June 2017

0 references

1 reference

1 reference

Singh B

1

1 reference

26 June 2017

Powrie F

series ordinal

2

1 reference

26 June 2017

Mortensen NJ

series ordinal

3

1 reference

26 June 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

British Journal of Surgery

26 June 2017

1 reference

26 June 2017

88

1 reference

26 June 2017

12

1 reference

26 June 2017

1558-1569

1 reference

Animal models of mucosal inflammation and their relation to human inflammatory bowel disease

26 June 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Cytokines induce the development of functionally heterogeneous T helper cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Interleukin 10 is a growth factor for a population of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Acquisition of lymphokine-producing phenotype by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Inflammatory bowel disease: etiology and pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Interleukin 12 and Th1 responses in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Role of cytokines in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Murine mentors: transgenic and knockout models of surgical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Colitis in transgenic and knockout animals as models of human inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

T cells in inflammatory bowel disease: protective and pathogenic roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Regulatory T cells: key controllers of immunologic self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Regulatory T cells in autoimmmunity*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

The role of IL-10 in inflammatory bowel disease: "of mice and men".

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Altered immune responses in interleukin 10 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Interleukin 10 gene transfer prevents experimental colitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Antibodies to interleukin 12 abrogate established experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Interleukin 15 activity in the rectal mucosa of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Response of human intestinal lamina propria T lymphocytes to interleukin 12: additive effects of interleukin 15 and 7

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Blockade of interleukin 6 trans signaling suppresses T-cell resistanceagainst apoptosis in chronic intestinal inflammation: Evidence in Crohn diseaseand experimental colitis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2001.01909.X

10.1046/J.0007-1323.2001.01909.X

21 January 2018

Identifiers

DOI

1 reference

26 June 2017

1 reference